Cours suspendu

Autres langues Merrimack Pharmaceuticals

Actions

MACK

US5903282094

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 17/05/2024			Varia. 5j.	Varia. 1 janv.
15,13 ^USD	-0,13%		-.--%	-

15/05/24	Merrimack Pharmaceuticals, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
09/05/24	Merrimack Pharmaceuticals, Inc. annonce le montant prévu du dividende final en espèces de la distribution liquidative initiale, payable le 17 mai 2024 ou aux alentours de cette date	CI

Autres langues

21/05/24	Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) dropped from S&P Global BMI Index
21/05/24	Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) dropped from S&P TMI Index
17/05/24	Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) dropped from NASDAQ Composite Index
15/05/24	Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
13/05/24	Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution and Cash Liquidating Dividend Amount of $15.10 per Share of Common Stock
10/05/24	Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock
09/05/24	Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Payable on or About May 17, 2024
09/05/24	Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of Dissolution
30/04/24	Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution
27/03/24	Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan
27/03/24	Merrimack Receives $225 Million Milestone Payment from Ipsen
07/03/24	Merrimack Reports Full Year 2023 Financial Results
07/03/24	Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
14/02/24	Merrimack Reports Ipsen Announcement of Approval by The US FDA of Onivyde Plus 5 Fluorouracil/Leucovorin and Oxaliplatin as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma
14/02/24	Merrimack Pharmaceuticals to Receive $225 Million Milestone Payment From Ipsen
13/02/24	Merrimack Pharmaceuticals to Get $225 Million Milestone Payment After FDA's Supplemental NDA Approval
13/02/24	Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
16/11/23	Merrimack Pharmaceuticals Insider Bought Shares Worth $627,125, According to a Recent SEC Filing
02/11/23	Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
02/11/23	Merrimack Reports Third Quarter 2023 Financial Results
18/09/23	Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to S&P Global BMI Index
09/08/23	Insider Buy: Merrimack Pharmaceuticals
03/08/23	Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
03/08/23	Merrimack Reports Second Quarter 2023 Financial Results
23/06/23	Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to Russell 3000E Growth Index